Endo Lidoderm Settlements: “Golden Goose” Hatches Strong Case
This article was originally published in RPM Report
Executive Summary
Off-label promotion prosecutions are supposed to be much tougher in the post-Caronia period. However, it is not too hard for the government to make a compelling case when a marketing manager calls one off-label use the “golden goose” for a product line.
You may also be interested in...
Acknowledging Caronia: FDA Takes The First Step To Rethinking Off-Label Policy
FDA has gotten past the denial phase and now is listening to ideas on how to balance the need to preserve the integrity of the regulatory process with evolving interpretations of the First Amendment as it applies to commercial speech. That is slow but important progress – but towards what goal?
Comparative Effectiveness May Be Next Battleground For First Amendment Fight With FDA
Lawyers suggest new avenue to challenge restrictions on off-label information; also say FDA appears to be doubling down in rejecting observational studies and comparative analyses.
Risperdal Settlement Shows False Claims Act Prosecutions Still Have Teeth After Caronia
A $2.2 billion settlement prompts another round of headlines about the pharmaceutical industry's marketing practices -- and no apparent indication that the Caronia ruling is changing the way prosecutors (and the public) perceive off-label promotion.